Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
“DESTINY-PanTumor02: post-hoc HER2 IHC concordance and T-DXd
- Phase II (n=267)
- local vs central: IHC 3+ – 59% | IHC 2+ – 55%
- ORR higher in IHC 3+ (~61%)
Moderate agreement, but activity maintained. Need for standardized HER2 testing in pan-tumor setting.”
Title: Post-Hoc Analysis of the Phase II DESTINY-PanTumor02 Study: Local and Central HER2 IHC Concordance and Trastuzumab Deruxtecan Efficacy by HER2 IHC Status in HER2-Expressing Solid Tumors
Authors: Vicky Makker, Jung-Yun Lee, Do-Youn Oh, Ana Oaknin, Soham Puvvada, Lindsey Jung, Robert McEwen, Flavia Michelini, Funda Meric-Bernstam
Other articles featuring Nieves Martinez Lago on OncoDaily.
